Monitor for follow-up filings to determine if these sales were under 10b5-1 plans; absence of material negative news suggests routine capital activity rather than distress signal.
Price Chart
Executive Summary
Multiple executives at Arcutis Biotherapeutics sold shares in a coordinated open-market transaction totaling $1.3M across four insiders, representing 0.04% of market cap. These sales coincided with routine stock award grants, a common practice around equity vesting events.
Key Financial Metrics
Key Facts
- Four insiders sold shares open-market for a total of $1,301,102 on March 2, 2026, at ~$25.16 per share
- Sellers include CFO Latha Vairavan and other named executive officers
- On February 27, the same insiders received stock awards totaling 196,000 shares (non-cash, $0 value)
- Total open-market sale value represents 0.04% of $3.1B market cap — below materiality threshold
- Sales appear related to pre-arranged 10b5-1 plans or tax/liquidity management following equity grants
Financial Impact
$1.3M in open-market sales, offset by no direct financial impact from non-cash grants
Risk Factors
- Perception of insider confidence if sales continue beyond planned schedules
- Potential dilution from 196,000 newly granted shares over time
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-ARQT-1772588560985 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | Insider Cluster | $24.86 $26.38 | ▲ +6.11% | ▲ +5.87% | $25.16 (+1.21%) |
Aug 21, 2026 6w ago | Insider Cluster | $25.08 $25.96 | ▲ +3.51% | ▲ +4.04% | $25.16 (+0.32%) |
Aug 19, 2026 6w ago | Insider Cluster | $25.35 $25.38 | ▲ +0.12% | ▲ +0.12% | $25.16 (−0.75%) |
Aug 11, 2026 7w ago | 144 | $26.28 $23.38 | ▼ −11.04% | ▼ −9.14% | $25.16 (−4.26%) |
Aug 6, 2026 8w ago | Insider Cluster | $26.43 $23.66 | ▼ −10.48% | ▼ −11.08% | $25.16 (−4.81%) |
Aug 5, 2026 8w ago | Press Release | $26.43 $23.66 | ▼ −10.48% | ▼ −11.08% | $25.16 (−4.81%) |
Aug 3, 2026 8w ago | 144 | $26.03 $23.75 | ▼ −8.76% | ▼ −7.52% | $25.16 (−3.34%) |
Jun 29, 2026 13w ago | Press Release | $26.22 $27.84 | ▲ +6.18% | ▲ +7.21% | $25.16 (−4.04%) |
Jun 18, 2026 15w ago | Insider Cluster | $26.21 $27.74 | ▲ +5.84% | ▲ +5.30% | $25.16 (−4.01%) |
Jun 9, 2026 16w ago | 8-K | $23.23 $28.78 | ▲ +23.89% | ▲ +20.27% | $25.16 (+8.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access